Patient Reported Toxicity, Quality of Life and Biochemical Control Following HDR Brachytherapy: Outcomes from the First 2 Years of a New Service at the Sussex Cancer Centre

Sharon A. Appleyard(Commonwealth Scientific and Industrial Research Organisation), Ashok Nikapota(University Hospitals Sussex NHS Foundation Trust), Andrew Johns(University Hospitals Sussex NHS Foundation Trust), Angus Robinson(Royal Sussex County Hospital), F. Cowtan(University Hospitals Sussex NHS Foundation Trust)
Clinical Oncology
January 25, 2019
10.1016/j.clon.2018.11.009
Cited by 0

Related Papers

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
|The Lancet Oncology|2019|649
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
|BORIS (University Library Bern)|2022|311